Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
Status:
COMPLETED
Trial end date:
2011-06-10
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are:
1. The effect of metformin on olanzapine-induced metabolic disturbance
2. The effect of metformin on olanzapine-induced hyperprolactinemia
Participants will receive metformin 1500 mg/day for 8 weeks and assessments every 2 weeks.